

PROTECT OUR CARE

MEMORANDUM

TO: Interested Parties

FROM: Leslie Dach and Brad Woodhouse, Protect Our Care

DATE: September 1, 2026

SUBJECT: Trump Has Done Nothing But Sell Out Americans To Enrich Big Drug Companies

No President has done more to enrich big drug companies and gaslight Americans on prescription drug costs than Donald Trump. While Trump makes false claims and waves [misleading headlines on drug prices](#) in front of reporters, millions of families are rationing doses, skipping refills, and diving deeper into their savings to afford prescriptions. Aside from marketing schemes and empty promises, Trump and Republicans have done nothing to lower drug prices for patients. The facts speak for themselves:

- Trump's [latest backroom](#) "deals" offer no details on how they'd save money for patients and have a history of only [enriching](#) drug companies and [himself](#).
- After Trump returned to office, drugmakers raked in [record-high revenue](#) while a [record-high two in three Americans](#) reported struggling to afford prescription drugs.
- More Americans than [ever before say](#) they can't afford to take their medication as prescribed.
- Under Trump, drug companies got away with hiking the prices of [more drugs than ever before](#).
- To make matters worse, Trump [robbed](#) seniors of lower prices on some of the costliest drugs for cancer, epilepsy, and multiple sclerosis and [hiked the price of drug coverage](#) for millions.
- TrumpRx [failed](#) to save the [vast majority](#) of Americans a single penny.

Trump Keeps the Handouts Coming for Corporations and Hikes Costs for Everyone Else

Trump has done nothing but put industry profits and his wealthy friends before lowering costs for the American people. Trump [entertained](#) drug company executives at his Mar-a-Lago resort before returning to office, [solicited](#) millions in donations, then spent the past year handsomely [rewarding](#) Big Pharma for their support. Trump helped big drug companies [evade billions](#) in taxes, escape tariffs, and [exempt](#) their top-selling products from drug price negotiations. He padded drugmakers' profits by an additional [\\$15 billion](#) with a [special tax break](#), [expanded the tax break](#) through the IRS, and gave Big Pharma an additional [\\$9 billion gift](#) at the expense of seniors and taxpayers. He carried out an executive order that read like an [industry wishlist](#), launched a [listening tour for company executives](#) instead of working people, [fast-tracked drug approvals](#) for special interests, and pushed for [more industry giveaways](#).

While he showered Big Pharma with gifts and distracted the public with sham announcements, Trump worked behind the scenes to raise costs for patients. In the so-called "One Big, Beautiful Bill," he handed Big Pharma their [biggest victory](#) in years by signing an [\\$8.8 billion](#) bailout designed to carve out top-selling products, such as lifesaving cancer drugs [Keytruda](#) and [Opdivo](#), from Medicare drug price negotiation. Per [The Wall Street Journal](#): "Thousands of Medicare recipients will have to wait longer to get some price relief on the expensive cancer drugs they depend on for treatment, while others might not get any reprieve at all." These seniors will pay thousands more each year for drugs that treat cancer, epilepsy, and multiple sclerosis thanks to Trump. To add insult to injury, Trump [terminated](#) a program that would allow seniors to purchase generic drugs for \$2, [eliminated](#) the FDA office tasked with speeding approvals of cheaper generic drugs, and [hiked](#) the cost of prescription drug coverage for

PROTECT OUR CARE

millions of seniors. Under Trump, drug companies are lining their pockets with [record-breaking](#) revenues while everyday Americans pay the price.

Read Protect Our Care's Report: [Greed Watch: Big Drug Companies Make Record-Breaking Sales While Seniors With Cancer Get Sold Out Thanks to Donald Trump](#)

TrumpRx Is An Utter Joke And His Backroom “Deals” Are Smoke and Mirrors

Trump is gaslighting the [millions](#) of Americans who are forced to skip prescriptions and ration doses every day with bogus claims that his sham deals and dressed-up coupon site are saving Americans “[1000%](#)” “[\\$700 million](#)” “[\\$500 billion](#)” and bringing people “[the lowest prices in the world](#)” on drugs. The painful truth couldn't be clearer: most Americans aren't saving a penny from Trump's dog-and-pony drug pricing show. More Americans than ever before are struggling with the cost of prescription drugs. GoodRx, the vendor behind the TrumpRx website, [admitted](#) that the website's “utilization appears to be incremental” and “has not had a material impact on our business to date.” His latest Medicaid drug pricing scheme will not benefit families since they [already pay almost nothing](#) for drugs and will soon be forced to [pay hundreds more out-of-pocket](#) for health care, if they do not lose their coverage altogether, thanks to Trump's health care cuts. Drug companies [celebrate](#) Trump's scam deals at shareholder calls, boasting about how they escaped tariffs and more legitimate [efforts to lower prices](#). Analysts spoke of how the deals are “[immaterial](#)” to drug companies' bottom lines and “likely [a win for the pharmaceutical industry](#).” The industry's worst-kept secret is that Trump's “deals” are nothing but smoke and mirrors that benefit big drug companies more than working families.

Read Protect Our Care's Fact Sheet: [10 Reasons Why TrumpRx Is an Utter Joke](#)

Trump and Republicans Profit From Prescription Drug Industry Corruption But Can't Fool the American People

While Trump and Republicans in Congress pad industry profits with handout after handout, raking in corporate donations in return isn't enough to satisfy them. They are doubling down on their greed by investing in the same pharmaceutical companies making windfalls from their policies. Trump bought up to [\\$680,000](#) in Eli Lilly stock this year just as the company stands to rake in profits from Medicare coverage of their GLP-1 drugs. Trump's GLP-1 Bridge program is expected to be a [huge windfall](#) to Eli Lilly, [leave behind](#) many of the seniors who need the drug the most, and offer only temporary assistance to those who qualify. Republican lawmakers in Congress also invested [\\$1.8 million](#) in drug companies in the first six months of the Trump administration, betting on the passage of their giant [\\$9 billion handout](#) exempting or delaying companies' bestselling drugs from Medicare drug price negotiation.